Aridis Pharma Founder & CEO Discusses Upcoming Milestones for its Late-Stage Pipeline
Jul. 10, 2023
Aridis (Nasdaq: ARDS) is revolutionizing how we treat infectious diseases through its unique technology platforms, which can quickly detect human-derived mAbs to treat infectious diseases. The Company's transformative approach utilizes a patient's own immune system to identify mAbs capable of fighting infections and underpins multiple late-stage programs. In January, Aridis announced positive top-line data from the first of two Phase 3 studies of its lead candidate, AR-301, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). In March, Aridis announced positive top-line data from its Phase 2a trial in cystic fibrosis, meeting primary and second endpoints for the study. Aridis received agreement from the FDA for a single confirmatory Phase 3 study of AR-301 in May 2023 and is discussing results of its CF study with the FDA and the EMA to plan the definitive next steps. The Cystic Fibrosis Foundation is the largest shareholder of Aridis and has invested $12.5 million into the Company to date. Learn more at AridisPharmainfo.com.
